Form D · Biotechnology

AI3 Bio, Inc.

Watertown, MA · CIK 0002019875

Offering snapshot reported Nov 4, 2026 · SEC filing

Reported sold
$48.3M
Offering amount: $48.3M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 9, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 4, 2026Initial$48,339,490No comparison8SEC filing
Nov 4, 2026Initial$0No comparison7SEC filing
Oct 20, 2025Initial$16,754,446No comparison4SEC filing
Aug 11, 2025Amendment$58,510,656No comparison14SEC filing
Apr 30, 2025Amendment$53,441,210$2,500,000vs Apr 23, 202414SEC filing
Apr 23, 2024Initial$50,941,210No comparison14SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-603654

Source: Form D, filed Nov 4, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steve Altschuler Director, Executive
Steven Altschuler Director, Executive
Andrew Bellinger Director
Andrew Cornforth Executive
Jeanne Cunicelli Director
Alan Ezekowitz Director
Nichols Garrett Executive
Jonathan Kagan Executive
Jeffrey Karp Executive
Michael Lyman Executive
Richard Malley Director
Garrett Nichols Executive
Nick Seaver Director, Executive
Fabian Tenenbaum Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
99 Coolidge Ave, Suite 201
Watertown, MA, 02472